Activities in the Life Science Business

The Fujifilm Group began marketing X-ray films in 1936, soon after its foundation, and now we expand our business worldwide for X-ray diagnosis, Sonography diagnosis, and Endoscope diagnosis. We have long been deeply involved in the medical field and have recently been fostering proactive expansion strategies to make medical and health care business one of our core businesses.

We call the diagnosis business in which we have already achieved significant results the “Life Imaging/Information” field and we now aim to expand our business to include the “Life Safety/Security” field (such as an air purifier) and the “Life Cure/Care” field (treatment and preventive medicine). In other words, we will be involved with “life” from various aspects in our life science business.

The Fujifilm Group was an expert in the diagnostic imaging of morphologies. For example, in X-ray examinations of tuberculosis, images of the inflamed area were taken for diagnosis. Now, however, as a result of establishing FUJIFILM RI Pharma in 2007,^*1 our diagnostic imaging technology has been advanced to a level where we can take images of the functioning of the body. This company is an expert in radiopharmaceuticals, and by combining its technologies with our existing diagnostic systems, we can now provide medical practitioners with systems to check even the functioning of internal tissue, including the functioning of internal organs and intralesional situations.

In addition to advancing the level of diagnosis, the introduction of radiopharmaceuticals has also contributed to the better treatment of disease. Radiopharmaceuticals are useful for the diagnosis of lesions, including those caused by cancers, and can also work as therapeutic radiopharmaceuticals if the function to suppress the pathogen is added to the medical agent. In February 2009, we became more involved in this business by increasing our stake in Perseus Proteomics, a venture concerned with antibody-based therapeutics,^*2 to more than 75%, making it a subsidiary. The Fujifilm Group is thus further advancing its diagnostic imaging technology by adding the imaging of functioning and expanding its life science business to integrate the fields of diagnosis and treatment.

• *1 Established by acquiring shares in Daiichi Radioisotope Laboratories, Ltd. and changing the corporate name
• *2 Pharmaceutical agents that make use of the natural immune system, specifically antibodies that bind with specified proteins

We made great progress in the field of treatment after Toyama Chemical joined the Fujifilm Group in 2008. This R&D-oriented company was founded in 1936 and achieved its growth through its synthesis technology. At present, it focuses on anti-infective agents, CNS and cardiovascular agents, and anti-inflammatory agents and is one of the top companies in terms of the number of new drugs marketed. On the other hand, FUJIFILM has a library of more than 200,000 chemical compounds as a result of its R&D activities for photographic film. Combining this valuable library, which provides the “source” for developing new drugs, with the technologies of Toyama Chemical, we aim to dramatically expand the range and accelerate the speed of drug discovery. Moreover, the FTD technology^*3 developed by FUJIFILM has a lot in common with the drug delivery technology^*4 for pharmaceuticals. If it becomes possible to deliver a medical agent to its destination in the appropriate amount and manner using FTD technology, concerns over side effects will decrease and the latitude for new drug development will be substantially increased.

We will also expand our business further and faster in the area of prevention, where we have Astalift (cosmetics developed based on research into collagens and antioxidation technologies) as well as Metabarrier and Oxibarrier (nutritional supplements).

• *3 Formulation, targeting and delivery (FTD) technology is a technology to formulate ingredients and materials functionally into the desired chemicals and deliver them to targeted sites freshly, stably, and timely in an appropriate amount to ensure the durability of the effect
• *4 Technology to deliver medical agents effectively to the targeted diseased part